MAP2K7 and melanoma: Important insights can be drawn by analyzing clinical trials and meta-analysis: first, BRAF inhibitors, potentially in combination with MEK-inhibitors, might be a valuable therapeutic option for the treatment of recurrent BRAF mutated high grade gliomas and melanoma brain metastases, thus we can argue that these drugs appear to effectively penetrate the blood-brain-barrier.